The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

BACKGROUND: Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Marseille, Elliot, Kahn, James G., Yazar-Klosinski, Berra, Doblin, Rick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556534/
https://www.ncbi.nlm.nih.gov/pubmed/33052965
http://dx.doi.org/10.1371/journal.pone.0239997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556534/
https://www.ncbi.nlm.nih.gov/pubmed/33052965
http://dx.doi.org/10.1371/journal.pone.0239997

Ejemplares similares